Article
Dr. Jack Cush answers audience clinical case questions sent by email or "ask Cush anything". Cases and questions from:
All News
Dr. Rachel Tate
Tweet
Hot off the press! Case report inspired by Dr. George Martin. Topical ruxolitinib efficacy in cutaneous DM. Dr. @susanshenoi #RWCS24 @RWCSmtg @RheumNow https://t.co/uyJdvgJ0ue
Dr. John Cush
Tweet
Ixekizumab Safety from 25 RCTs (17 PsO, 4 PsA, 4 axSpA) w/ 9225 pts (22371 PYs use). Long-term safety c/w earlier reports/PI. SAEs in 1204 (13%); 45 deaths); ISRs 5.9-11.6/100PYs; IBD ≤ 0.8/100PY; depression, CVA, Cancer : ≤ 1.6/100PY https://t.co/p7N6ZMVvqh https://t.co/22WYkevhaf
Dr. Rachel Tate
Tweet
Gut microbiota in SpA. Interesting data from @RWCSmtg @JointMD regarding the gut microbiome, both shared and distinct, in SpA, non-infectious AAU and Crohn's. #RWCS24 @RheumNow https://t.co/tHGl01WJ1o
Dr. Rachel Tate
Tweet
"It's hard not to be jealous of the dermatologists." @JointMD discussing the results of JNJ 77242113, po IL-23R, the Frontier 1 trial. #RWCS24 @RWCSmtg @RheumNow https://t.co/1zQ6bu5TM2
Dr. Rachel Tate
Tweet
Current PsA treatment options. A review with @RWCSmtg @JointMD #RWCS24 @RheumNow https://t.co/9I0TfyILvQ
Dr. Rachel Tate
Tweet
Combo IL-23 and TNFi synergistic benefit in UC in the proof-of-concept VEGA trial. More data to come! #RWCS24 @RWCSmtg @RheumNow https://t.co/FgLTR2PBYJ
Dr. Rachel Tate
Tweet
Adult vs Juvenile DM by @susanshenoi at #RWCS24 @RWCSmtg @RheumNow
Adults tend to have myalgia, arthralgia, raynauds vs kids with skin ulcerations and vasculopathy https://t.co/1DW2kJsLfa
Dr. Rachel Tate
Tweet
Dr. @susanshenoi reviews IIM in juveniles vs adults. Some highlights:
*IBM only in adults
*PM more common in adults
See picture for additional pearls
#RWCS24 @RWCSmtg @RheumNow https://t.co/onUEwkKXBN
Dr. Rachel Tate
Tweet
Dr. J. Giles reviews adipose tissue as a source of inflammatory cytokines like TNF, IL-6, IL-1, IL17, etc. #RWCS24 @RWCSmtg @RheumNow https://t.co/AYD9PpwNE6
Dr. Rachel Tate
Tweet
Weight loss is associated with reduced systemic inflammation in RA. If only discussing body composition/obesity/adiposity were that easy for our patients, these changes are hard and non-linear. Dr. Jon Giles #RWCS24 @RWCSmtg @RheumNow https://t.co/vrbBHLz6sL
Dr. Rachel Tate
Tweet
An updated medication list for diabetes medications with Dr. O. Troum at #RWCS24 @RheumNow @RWCSmtg https://t.co/ZYr5i7PAI9
Dr. Rachel Tate
Tweet
#RWCS24 @JointMD @RWCSmtg review the TNFi differences molecularly. @RheumNow https://t.co/6JAnNwwV0n
Dr. Rachel Tate
Tweet
"In solid tumors, treat your RA patient as if they do not have a cancer, meaning do not change your therapy if the patient is responding well. Things may get dicey if hematologic malignancy." @RheumNow #RWCS24
I work w/ my onc team to ensure the patient has the needed support.
Dr. Rachel Tate
Tweet
Anticardiolipin ab are the most frequent aPL in SLE. Dr. M. Petri #RWCS24 @RWCSmtg @RheumNow https://t.co/cCxhctLTGf
Dr. Rachel Tate
Tweet
Dr. Petri reviews the 2023 ACR/APS Classification Criteria at #RWCS24 @RheumNow @RWCSmtg https://t.co/FWGsFk02Dn
Dr. Rachel Tate
Tweet
Steroids are associated with MACE events in RA. #RWCS24 @RheumNow @RWCSmtg https://t.co/U6ssALNspe
Dr. Rachel Tate
Tweet
Controversial MOSAIC results. @JointMD and @RWCSmtg discuss nuances listed below. #RWCS24 @RheumNow https://t.co/aVRJpqHuUM
Dr. Rachel Tate
Tweet
Who do you watch closely for developing RA? @RheumNow and @RWCSmtg suggest additional risk factors for ratcheting closer to RA. #RWCS24 https://t.co/lV3I5emn72
Dr. Rachel Tate
Tweet
Obese patients more likely to have a lower DMARD response compared to under/normal weighted patients. This still needs to be evaluated on a personal patient level, however, this is an important, layered discussion to have. #RWCS24 @RWCSmtg @rheumnow https://t.co/KIkVXQdcPm
